Almirall to pay $6.6 million to resolve whistleblower claims on kickbacks to doctors

30 May 2019

Spanish dermatology specialist Almirall (ALM: MC) and its US affiliate, formerly known as Aqua Pharmaceuticals, have agreed to pay the United States $3.5 million to resolve allegations that they used kickbacks to induce physicians to purchase their dermatology products.

The California Department of Insurance also settled a separate, but similar, claim on behalf of that state against the companies for $3.1 million at the same time.

The settlements stem from a whistleblower complaint filed by a former employee of Aqua pursuant to the qui tam provisions of the False Claims Act.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK